Table 1.
Patient Characteristics
| Characteristics | n (%) |
|---|---|
| Sex | |
| Male | 67 (61) |
| Female | 43 (39) |
| Disease | |
| ALL/AML/MDS | 44 (40) |
| CML | 7 (6) |
| CLL | 10 (9) |
| Lymphoma | 22 (20) |
| Multiple myeloma | 9 (8) |
| Aplastic anemia/PNH | 3 (3) |
| Other | 15 (14) |
| Stem cell source | |
| Bone marrow | 18 (16) |
| Peripheral Blood | 89 (81) |
| Cord Blood | 3 (3) |
| Donor-recipient relationship | |
| Related | 53 (48) |
| Unrelated | 57 (52) |
| Classification | |
| Classic cGvHD | 85 (78) |
| Overlap cGvHD | 22 (20) |
| Late acute cGvHD | 2 (2) |
| cGvHD onset | |
| Progressive | 33 (30) |
| Quiescent | 38 (35) |
| De novo | 38 (35) |
| Therepeutic intent | |
| Active | 65 (64) |
| Not active | 37 (36) |
| TBI conditioning | |
| Yes | 46 (43) |
| No | 62 (57) |
| Karnofsky score | |
| 40–70 | 44 (40) |
| 80–100 | 66 (60) |
| Current systemic treatments | |
| Prednisone, dexamethasone, budesonide | 100 (90) |
| Azathioprine, mycophenolate mofetil | 62 (56) |
| mTOR inhibitors | 21 (20) |
| Calcineurin inhibitors | 37 (34) |
| mTOR inhibitors+ Calcineurin inhibitors | 7 (6) |
| Misc others* | 73 (66) |
| Platelet Count | |
| <100 × 109 | 5 (4) |
| <150 × 109 | 11 (10) |
| >150× 109 | 94 (86) |
| Intensity of immunosuppression+ | |
| None/mild | 22 (20) |
| Moderate | 40 (36) |
| High | 48 (44) |
| Prednisone dose per kg | |
| >0, <0.50 | 50 (45) |
| >0.50 | 19 (17) |
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; cGVHD, chronic graft-versus-host disease; CLL, chronic lymphocytic leukemia; MDS, myelodysplastic syndrome; PNH, paroxysmal nocturnal hemoglobinuria.
Rituximab, ECP, PUVA, Etanercept, Daclizumab, IVIG, Ontak, Thalidomide, Hydroxychloroquine, Imatinib.
Active cGvHD by therapeutic intent at the time of the visit: (1) increase systemic therapy because cGVHD is worse; (2) substitute systemic therapy due to lack of response; and (3) withdraw systemic therapy due to lack of response. Non-active: (1) decrease systemic therapy because cGVHD is better; (2) not change current systemic therapy because cGVHD is stable; (3) alter systemic therapy owing to its toxicity. Other: either did not receive any immunosuppressive therapy or did not meet any of the criteria.10
None/mild, single-agent prednisone 0.5 mg/kg per day; moderate, single-agent prednisone 0.5 mg/kg/day and/or any single agent/modality; high, 2 or more agents/modalities ± prednisone 0.5 mg/kg/day.